CN112996911A - 用于制造和疗法的脱氧核糖核酸酶的工程改造 - Google Patents

用于制造和疗法的脱氧核糖核酸酶的工程改造 Download PDF

Info

Publication number
CN112996911A
CN112996911A CN201980073970.5A CN201980073970A CN112996911A CN 112996911 A CN112996911 A CN 112996911A CN 201980073970 A CN201980073970 A CN 201980073970A CN 112996911 A CN112996911 A CN 112996911A
Authority
CN
China
Prior art keywords
variant
seq
amino acid
linker
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980073970.5A
Other languages
English (en)
Chinese (zh)
Inventor
托碧昂斯·A·富驰
R·阿卜杜勒·哈金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutrex Co ltd
Original Assignee
Neutrex Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrex Co ltd filed Critical Neutrex Co ltd
Publication of CN112996911A publication Critical patent/CN112996911A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
CN201980073970.5A 2018-10-08 2019-10-08 用于制造和疗法的脱氧核糖核酸酶的工程改造 Pending CN112996911A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862742682P 2018-10-08 2018-10-08
US62/742,682 2018-10-08
US201862775563P 2018-12-05 2018-12-05
US62/775,563 2018-12-05
US201862779104P 2018-12-13 2018-12-13
US62/779,104 2018-12-13
US201962808601P 2019-02-21 2019-02-21
US62/808,601 2019-02-21
US201962846904P 2019-05-13 2019-05-13
US62/846,904 2019-05-13
PCT/US2019/055178 WO2020076817A1 (en) 2018-10-08 2019-10-08 Engineering of dnase enzymes for manufacturing and therapy

Publications (1)

Publication Number Publication Date
CN112996911A true CN112996911A (zh) 2021-06-18

Family

ID=70164727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980073970.5A Pending CN112996911A (zh) 2018-10-08 2019-10-08 用于制造和疗法的脱氧核糖核酸酶的工程改造

Country Status (12)

Country Link
US (5) US10988746B2 (enExample)
EP (1) EP3864147A4 (enExample)
JP (3) JP2022504400A (enExample)
KR (1) KR20210072790A (enExample)
CN (1) CN112996911A (enExample)
AU (2) AU2019358915B2 (enExample)
BR (1) BR112021006737A2 (enExample)
CA (1) CA3115766A1 (enExample)
IL (2) IL325846A (enExample)
MX (1) MX2021004022A (enExample)
SG (1) SG11202103426XA (enExample)
WO (1) WO2020076817A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120424194A (zh) * 2025-04-30 2025-08-05 苏州泓迅生物科技股份有限公司 一种重组人源纤连蛋白的制备方法及其应用
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 上海交通大学医学院 一种减少线粒体dna泄露的方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
CN112996911A (zh) * 2018-10-08 2021-06-18 纽特雷斯股份有限公司 用于制造和疗法的脱氧核糖核酸酶的工程改造
US11352613B2 (en) * 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
US20230072226A1 (en) * 2020-02-20 2023-03-09 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
CA3181572A1 (en) * 2020-06-08 2021-12-16 Paul STABACH Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
KR20240004247A (ko) * 2021-02-17 2024-01-11 뉴트롤리스 인코포레이티드 요법에서 제조 및 사용하기 위해 조작된 dnase 1-유사 2
WO2022246139A1 (en) * 2021-05-21 2022-11-24 Genkin Dmitry Dmitrievich Immunomodulation of tumor microenvironment
EP4448743A4 (en) * 2021-12-15 2026-01-14 Univ Texas Tech System IMPROVEMENT IN THE SERUM HALF-LIFE OF DNASE1L3
US20250179451A1 (en) * 2022-02-23 2025-06-05 Neutrolis, Inc. Dnase enzymes engineered for improved stability
EP4788836A1 (en) * 2023-10-06 2026-08-12 Neutrolis, Inc. Biomarker and precision therapy for inflammatory disease

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138156A1 (en) * 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
CN103732628A (zh) * 2011-03-03 2014-04-16 酵活有限公司 多价杂多聚体骨架设计和构建体
CN103930127A (zh) * 2011-04-29 2014-07-16 华盛顿大学 治疗性核酸酶组合物和方法
CN104039830A (zh) * 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
EP3570667A1 (en) * 2017-01-20 2019-11-27 Universitätsklinikum Hamburg-Eppendorf Animal model for drug development
US20200115690A1 (en) * 2018-10-08 2020-04-16 Neutrolis, Inc. Manufacturing and engineering of dnase enzymes for therapy
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
WO2022178110A2 (en) * 2021-02-17 2022-08-25 Neutrolis, Inc. Dnase 1-like 2 engineered for manufacturing and use in therapy
CN120435552A (zh) * 2022-11-14 2025-08-05 纽特雷斯股份有限公司 经工程化以改进表达的dna酶1样蛋白3及在疗法中的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
DK2086642T3 (da) 2006-10-18 2014-09-29 Periness Ltd Dnase til behandling af subfertilitet hos mænd
EP2076592B1 (en) 2006-10-23 2017-04-12 Medical Research Council Polymerase
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
HUE041426T2 (hu) * 2009-11-02 2019-05-28 Univ Washington Terápiás nukleáz-készítmények és eljárások
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
US9644197B2 (en) * 2010-06-04 2017-05-09 Sk Chemicals Co., Ltd. Fusion protein having factor VII activity
US9198957B2 (en) 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
WO2012122477A1 (en) * 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
CA2858983C (en) 2011-12-12 2020-06-09 The Board Of Trustees Of The University Of Illinois Composition and method for treating nucleic acid-related eye disease
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
SI3063275T1 (sl) * 2013-10-31 2020-02-28 Resolve Therapeutics, Llc Terapevtske fuzije nukleaza-albumin in postopki
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
JP2017527618A (ja) 2014-09-08 2017-09-21 ゴッサム バイオファーマシューティカルズ，インコーポレイティド 肺サルコイドーシスの治療方法
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
CN110199015A (zh) 2016-09-30 2019-09-03 波赛达治疗公司 修饰干细胞记忆t细胞、其制造方法与使用方法
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
UA129696C2 (uk) * 2017-08-18 2025-07-09 Ньютроліс Інк. СКОНСТРУЙОВАНІ ФЕРМЕНТИ ДНКази ТА ЇХНЄ ЗАСТОСУВАННЯ В ТЕРАПІЇ
US20220025343A1 (en) * 2019-02-04 2022-01-27 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040138156A1 (en) * 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
CN103732628A (zh) * 2011-03-03 2014-04-16 酵活有限公司 多价杂多聚体骨架设计和构建体
CN103930127A (zh) * 2011-04-29 2014-07-16 华盛顿大学 治疗性核酸酶组合物和方法
CN107964539A (zh) * 2011-04-29 2018-04-27 华盛顿大学 治疗性核酸酶组合物和方法
CN104039830A (zh) * 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
EP3570667A1 (en) * 2017-01-20 2019-11-27 Universitätsklinikum Hamburg-Eppendorf Animal model for drug development
US20200115690A1 (en) * 2018-10-08 2020-04-16 Neutrolis, Inc. Manufacturing and engineering of dnase enzymes for therapy
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
WO2022178110A2 (en) * 2021-02-17 2022-08-25 Neutrolis, Inc. Dnase 1-like 2 engineered for manufacturing and use in therapy
CN117177990A (zh) * 2021-02-17 2023-12-05 纽特雷斯股份有限公司 用于制备的工程dna酶1样2和在治疗中的用途
CN120435552A (zh) * 2022-11-14 2025-08-05 纽特雷斯股份有限公司 经工程化以改进表达的dna酶1样蛋白3及在疗法中的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
徐诗佳等: "陆地棉C2H2锌指蛋白基因GhBsr-d1L3基因的VIGS载体构建", 新疆农业大学学报, 30 March 2022 (2022-03-30), pages 1 - 15 *
祝雯;谢东扬;林奇英;谢联辉;吴祖建;: "杨树菇中一种脱氧核糖核酸酶的纯化及其性质", 中国生物制品学杂志, no. 10, 20 October 2008 (2008-10-20), pages 1 - 10 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037276A1 (zh) * 2024-08-12 2026-02-19 上海交通大学医学院 一种减少线粒体dna泄露的方法
CN120424194A (zh) * 2025-04-30 2025-08-05 苏州泓迅生物科技股份有限公司 一种重组人源纤连蛋白的制备方法及其应用

Also Published As

Publication number Publication date
IL325846A (en) 2026-03-01
KR20210072790A (ko) 2021-06-17
IL282058B2 (en) 2026-06-01
WO2020076817A1 (en) 2020-04-16
US20200115690A1 (en) 2020-04-16
EP3864147A1 (en) 2021-08-18
IL282058A (en) 2021-05-31
CA3115766A1 (en) 2020-04-16
EP3864147A4 (en) 2022-07-06
JP2022504400A (ja) 2022-01-13
AU2019358915B2 (en) 2025-09-18
JP2024160327A (ja) 2024-11-13
US20210207114A1 (en) 2021-07-08
JP7818850B2 (ja) 2026-02-24
AU2019358915A1 (en) 2021-05-20
US20240191218A1 (en) 2024-06-13
SG11202103426XA (en) 2021-05-28
US10988746B2 (en) 2021-04-27
US11578314B2 (en) 2023-02-14
AU2025283522B2 (en) 2026-03-19
AU2025283522A1 (en) 2026-01-15
IL282058B1 (en) 2026-02-01
US20260152732A1 (en) 2026-06-04
US11840712B2 (en) 2023-12-12
US20220162575A1 (en) 2022-05-26
US12565642B2 (en) 2026-03-03
BR112021006737A2 (pt) 2021-07-13
JP2026082949A (ja) 2026-05-19
MX2021004022A (es) 2021-09-10

Similar Documents

Publication Publication Date Title
US12565642B2 (en) Engineered DNASE enzymes for thrombosis therapy
US20090169553A1 (en) Novel Protein Fusion/Tag Technology
HU227996B1 (hu) A von Willebrand faktort (vWF) hasító proteáz polipeptid, a polipeptidet kódoló nukleinsav, és a polipeptid használata
US20240374643A1 (en) Dnase1-like 3 and its use in therapy
ES2627066T3 (es) Proteínas elastasas recombinantes y procedimientos de fabricación y uso de las mismas
US20240401015A1 (en) Dnase enzymes engineered for improved stability
JPH07509229A (ja) ウシ膵トリプシン阻害因子から誘導される因子Ｘａの阻害因子
JP2738428B2 (ja) トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
JP2025538873A (ja) 発現の改善と治療への使用のために操作されたｄｎａｓｅ１－ｌｉｋｅ３
JPH04505554A (ja) 可溶性トロンボモジュリン類似体
JP3490444B2 (ja) 昆虫類の唾液からのトロンビン阻害剤
US20250129347A1 (en) Engineered human extracellular dnase enzymes
EA046216B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
EA052450B1 (ru) РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
JPH0757192B2 (ja) 新規なｄｎａ
JPH04234988A (ja) ヒトプロラクチン−プロテインａ融合蛋白発現遺伝子
HK1232783B (en) Uti fusion proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination